Bausch Health (BHC) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
19 May, 2026Opening remarks and agenda
Meeting commenced with a welcome from the CEO, who introduced the board nominees and executive team, and confirmed the presence of the independent auditor representative.
Confirmation of proper notice, quorum, and appointment of a scrutineer for the meeting.
Board and executive committee updates
Ten director nominees were introduced, including new and continuing members with diverse backgrounds in finance, pharmaceuticals, and law.
Shareholder proposals
Three items were presented for shareholder voting: election of directors, advisory vote on executive compensation, and appointment of auditors.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Bausch Health
- Q2 2026 saw double-digit growth, record margins, raised guidance, and a $1.43B Salix impairment.BHC
Q2 2026 - Sustained growth, robust liquidity, and strategic flexibility underpin future value creation.BHCBarclays 30th Annual Leveraged Finance Conference 2026
- Sustained growth, China expansion, and BLCO monetization drive strategic priorities.BHCRBC Capital Markets Global Healthcare Conference 2026
- Double-digit revenue and EBITDA growth, but a $1.43B goodwill impairment drove a net loss.BHCQ1 2026
- Board recommends approval of all proposals, with strong focus on pay-for-performance and ESG.BHCProxy filing
- Director elections, executive pay, and auditor appointment up for virtual shareholder vote.BHCProxy filing
- 11th straight quarter of revenue and EBITDA growth, with strong outlook and lower net debt.BHCQ4 2025
- Q3 revenue up 12%, Adjusted EBITDA up 10%, guidance raised, and net loss narrowed.BHCQ3 2024
- Q2 2024 revenue up 11% to $2.40B, adjusted EBITDA up 10%, and guidance raised.BHCQ2 2024